CABA241220P12500
- 9.30
- 0.000.00%
Cabaletta Bio Newsroom
Cabaletta Bio Presents Positive Data On CABA-201 At ACR Convergence 2024
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
Cabaletta Bio Reports Q3 2024 Financial Results
Express News | Cabaletta Bio Announces Presentation Of Updated CABA-201 Clinical Data At ACR Convergence 2024l; Says Safety Profile Suggested Favorable Risk-Benefit With No CRS Or ICANS In Majority Of Patients
Cabaletta Bio's CABA-201 Shows Results in Autoimmune Disease Trials
William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating
Cabaletta Bio Is Maintained at Overweight by Wells Fargo
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25
A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $12 to $25
Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Express News | Cabaletta Bio, Inc. : Wells Fargo Cuts Target Price to $12 From $20
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)
Strong Momentum and Promising Data Drive Buy Opportunity for Cabaletta Bio's CABA-201
Cabaletta Bio's Promising Trial Results and Proactive Management Secure Buy Rating
Cabaletta Bio Reports Q3 EPS (62c), Consensus (61c)
Cabaletta Bio | 10-Q: Q3 2024 Earnings Report
Cabaletta Bio | 8-K: Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Express News | Cabaletta Bio: Cash, Cash Equivalents & Short-Term Investments Total $183.0 Mln as of Sept 30, Expected to Support Operations Into H12026
Express News | Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Express News | Cabaletta Bio Q3 Net Income USD -30.629 Million Vs. IBES Estimate USD -29.9 Million